

## Covalon Announces Voting Results From 2018 Annual Meeting Of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Mar. 9, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the results of the matters voted upon at the Company's 2018 Annual Meeting of Shareholders held March 8th 2018.

Shareholders voted in favour of all items of business and each was approved by the requisite number of votes. The matters included the election of the board of directors, the appointment of auditors, and the approval of the Company's stock option plan. The total number of shares represented, either in person or by proxy, totaled 11,474,211 or 53.38%. The voting results are detailed below.

### 1) The Election of the Board of Directors:

Name of Nominee	Votes FOR	%	Votes WITHHELD	%
Abe Schwartz	10,969,593	99.50%	54,899	0.50%
Brian Pedlar	10,980,593	99.60%	43,899	0.40%
Martin Bernholtz	11,013,483	99.90%	11,009	0.10%
Ian Brindle	10,980,602	99.60%	43,890	0.40%
Elinor Caplan	11,024,492	100.00%	0	0.00%
Joseph Cordiano	11,024,483	100.00%	9	0.00%
Jeffrey Mandel	10,969,602	99.50%	54,890	0.50%
Murray Miller	11,024,492	100.00%	0	0.00%
Gale Pollock	11,024,483	100.00%	9	0.00%

### 2) The Appointment of the Auditor:

	Votes FOR	%	Votes WITHHELD	%
BDO Canada LLP	11,439,011	100.00%	0	0%

### 3) The Approval of the Corporation's 2007 Stock Option Plan:

	Votes FOR	%	Votes WITHHELD	%
Stock Option Plan	10,815,102	98.10%	209,390	1.90%

Final voting results of all matters voted on at the meeting will be filed on SEDAR at [www.sedar.com](http://www.sedar.com) and further details of the voted matters can be found in the Company's proxy circular with a record date of January 22nd 2018.

### About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at [www.covalon.com](http://www.covalon.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the*

*results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.*

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180309005408/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.

Brian Pedlar, 905-568-8400 x 233

CEO

[bpedlar@covalon.com](mailto:bpedlar@covalon.com)

Toll free: 1-877-711-6055

[www.covalon.com](http://www.covalon.com)

Twitter: @covalon

---

<https://ir.covalon.com/press-releases?item=140>